

PG4893USW

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Beswick et al.

Serial No.: 10,527,799

Group Art Unit: 1614

File Date: August 17, 2005

Examiner: To be assigned

For: COX-2 Inhibiting Pyrimidine Derivatives

**Director of the U.S. Patent and Trademark Office****P.O. Box 1450****Alexandria, VA 22313-1450****SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97. Copies of the references are enclosed, i.e., references 18-53.

Applicants note that two of the references (references 52 and 53 from the PTO-1449) are internally generated studies of the compound of Example 54 in the instant Application. The two references have been redacted from their original versions. Redacted portions of the references are indicated with "[\*\*\*\*]". The compound identifier for the compound of Example 54 is indicated with "[\*54\*]".

Notice of Co-pending Applications. The Examiner is requested to please take note of the following co-pending applications which are commonly owned.


Serial No.	Filing Date
09/830,836	5/1/2003
10/362,745	6/25/2003
10/506,934	3/13/2003
10/524,462	2/14/2005
10/527,799	3/15/2005
10/535,806	11/21/2003
10/568,399	2/11/2006
10/974,893	10/27/2004
11/110,118	4/20/2005
11/119,653	5/2/2005
11/165,073	6/23/2005

The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

☒ Please charge any required fees to Deposit Account No.07-1392.

☐ A duplicate copy of this paper is attached.

Respectfully Submitted,

  
J. Scott Young  
Registration No. 45,582

Date: *July 28, 2006*

GlaxoSmithKline

Corporate Intellectual Property

5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-8160

Facsimile: (919) 483-7988

<b>FORM PTO-1449</b> <b>INFORMATION DISCLOSURE STATEMENT</b>				<b>ATTORNEY DOCKET NO.</b> PG4893USW		<b>SERIAL NO.</b> 10/527,799	
				<b>APPLICANT:</b> Beswick et al.			
				<b>FILING DATE:</b> August 17, 2005		<b>GROUP</b> 1614	
<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initials	Serial Number	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	1	2003/0013717	Jan. 16, 2003	Mangel et al.			
	2	3,149,109	Sept. 15, 1964	Ncustaedter et al.			
	3	3,592,895	July 13, 1971	Hcpworth et al.			
	4	5,474,995	Dec. 12, 1995	Ducharme et al.			
	5	5,760,068	June 2, 1998	Talley et al.			
	6	5,972,986	Oct. 26, 1999	Seibert et al.			
	7	6,020,343	Feb. 1, 2000	Belley et al.			
	8	6,153,619	Nov. 28, 2000	Wood et al.			
	9	6,306,866	Oct. 23, 2001	Wood et al.			
	10	6,313,072	Nov. 6, 2001	Scheiblich et al.			
	11	6,451,794	Sept. 17, 2002	Beswick et al.			
	12	6,498,166	Dec. 24, 2002	Campbell et al.			
	13	6,756,498	June 29, 2004	Fitzgerald et al.			
	14	6,759,413	July 6, 2004	Mangel et al.			
	15	6,803,463	Oct. 12, 2004	Mathews et al.			
	16	6,831,097	Dec. 14, 2004	Beswick et al.			
	17	6,861,249	Mar. 1, 2005	Kent			
Continue on page							
<b>FOREIGN PATENT DOCUMENTS</b>							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes   No
	18	DB 19909541	Mar. 4, 1999	GERMANY			Abstract only
	19	WO 96/24585	Aug. 15, 1996	WIPO			
	20	WO 96/41645	Dec. 27, 1996	WIPO			
	21	WO 96/07641	Mar. 14, 1996	WIPO			Abstract only
	22	WO 98/16227	Apr. 23, 1998	WIPO			
	23	WO 98/24782	June 11, 1998	WIPO			
	24	WO 99/01439	Jan. 14, 1999	WIPO			
	25	WO 01/38311	May 31, 2001	WIPO			
	26	WO 02/18374	Mar. 7, 2002	WIPO			
	27	WO 02/26216	May 11, 2000	WIPO			Abstract only
	28	WO 02/96427	Dec. 5, 2002	WIPO			
	29	WO 02/96885	Dec. 5, 2002	WIPO			
	30	WO 02/96886	Dec. 5, 2002	WIPO			
	31	WO 03/77920	Sept. 25, 2003	WIPO			
	32	WO 03/14091	Feb. 20, 2003	WIPO			
	33	WO 04/18452	Mar. 4, 2003	WIPO			
	34	WO 04/24691	Mar. 25, 2004	WIPO			
	35	WO 04/48344	June 10, 2004	WIPO			
Continue on page 2							
<b>EXAMINER</b>					<b>DATE CONSIDERED</b>		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

<b>FORM PTO-1449</b> <b>INFORMATION DISCLOSURE STATEMENT</b>				<b>ATTORNEY DOCKET NO.</b> PG4893USW		<b>SERIAL NO.</b> 10/527,799	
				<b>APPLICANT:</b> Beswick et al.			
				<b>FILING DATE:</b> August 17, 2005		<b>GROUP</b> 1614	
<b>U.S. PATENT DOCUMENTS</b>							
<b>Examiner Initials</b>		<b>Patent Number</b>	<b>Issue Date</b>	<b>Name</b>	<b>Class</b>	<b>Subclass</b>	<b>Filing Date If Appropriate</b>
Continue on page							
<b>FOREIGN PATENT DOCUMENTS</b>							
		<b>Document Number</b>	<b>Publication Date</b>	<b>Country</b>	<b>Class</b>	<b>Subclass</b>	<b>Translation Yes   No</b>
	36	WO 99/12930	Mar 18, 1999	WIPO			
	37	WO 01/46194	June 8, 2001	WIPO			
	38	WO 00/52008	Sept 8, 2000	WIPO			
	39	WO 01/83479	Nov. 8, 2001	WIPO			
	40	WO 05/016924	Feb. 24, 2005	WIPO			
	41	WO 01/56573	Aug 9, 2001	WIPO			
	42	WO 01/41760	June 14, 2001	WIPO			
	43	WO 98/03484	Jan. 29, 1998	WIPO			
Continue on page							
<b>OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)</b>							
	44	Casanova, B., et al. "A Critical Review of the Current Pathogenesis of Multiple Sclerosis and Possible Future Trends." PubMed Abstract (Rev. Neurol. 28(9):909-915, May 1989.					
	45	Damasio, A.R., et al. Alzheimer's Disease and Related Dementias, Cecil Textbook of Medicine, Vol. 2, pp. 1992-1996, 1996.					
	46	Douglas, R.G., Jr. "Introduction to Viral Diseases: Cecil Textbook of Medicine, 20 <sup>th</sup> Edition, Vol. 2, pp. 1739-1747, 1996.					
	47	Freston, J.W., et al. Rationalizing Cyclooxygenase (COX) Inhibition for Maximal Efficacy and Minimal Adverse Events + Abstract, Am. J. Med. 107(6A):78S-88S; Discussion 89S, December 1999.					
	48	Layzer, R.B., et al. Degenerative Diseases of the Nervous System, Cecil Textbook of Medicine, 20 <sup>th</sup> Edition, Vol. 2, pp. 2050-2057, 1996.					
	49	Naesdal, J. et al. "Gastro-Duodenal Protection in an Era of Cyclo-Oxygenase-2-Selective Nonsteroidal Anti-inflammatory Drugs." PubMed Abstract, Eur J Gastroenterol Hepatol, 13(12):1401-1406, December 2001.					
	50	Simone, J.V., et al. "Oncology: Introduction, Cecil Textbook of Medicine, 20 <sup>th</sup> Edition, Vol. 1, pp. 1004-10, 1996.					
	51	Stanghellini, V., et al. "Risk Indicators of Delayed Gastric Emptying of Solids in Patients With Functional Dyspepsia." Gastroenterology, 110, 1996, pgs. 1036-1042.					
	52	GlaxoSmithKline Internal Report, PAMS Summary Report for [*54] in HTB In Vivo Screening (1st PAMS) (redacted), May 15, 2005					
	53	GlaxoSmithKline Internal Report, The Cox-2 Inhibitor [*54*] is Effective in Rat Models of Inflammatory Pain (redacted), July 15, 2005.					
Continue on page							
<b>EXAMINER</b>					<b>DATE CONSIDERED</b>		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							